Richard E Pratley Selected Research

Body Weight (Weight, Body)

1/2024	Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
1/2023	Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
10/2022	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
1/2022	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
1/2022	Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
12/2021	High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice.
11/2021	An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
10/2021	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
4/2021	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.
11/2020	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard E Pratley Research Topics

Disease

98	Type 2 Diabetes Mellitus (MODY) 02/2024 - 02/2002
31	Insulin Resistance 01/2022 - 03/2002
24	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/2024 - 04/2015
23	Hypoglycemia (Reactive Hypoglycemia) 10/2023 - 04/2007
21	Obesity 05/2023 - 03/2002
19	Cardiovascular Diseases (Cardiovascular Disease) 02/2024 - 02/2005
19	Body Weight (Weight, Body) 01/2024 - 01/2008
14	Myocardial Infarction 01/2023 - 07/2006
13	Stroke (Strokes) 01/2023 - 07/2016
13	Hyperglycemia 01/2020 - 04/2007
12	Weight Loss (Weight Reduction) 01/2023 - 01/2008
12	Inflammation (Inflammations) 11/2018 - 02/2002
10	Heart Failure 10/2023 - 09/2006
9	Prediabetic State (Prediabetes) 01/2023 - 02/2010
8	Chronic Renal Insufficiency 01/2024 - 01/2018
7	Overweight 01/2023 - 01/2018
5	Kidney Diseases (Kidney Disease) 01/2024 - 01/2014
5	Weight Gain 01/2021 - 04/2011
4	Glucose Intolerance 12/2021 - 06/2002
3	Diabetes Mellitus 01/2023 - 11/2017
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2023 - 02/2008
3	Fibrosis (Cirrhosis) 01/2023 - 09/2006
3	Pancreatitis 01/2022 - 10/2021
3	Asthma (Bronchial Asthma) 10/2012 - 09/2010
2	COVID-19 03/2023 - 11/2022
2	Non-alcoholic Fatty Liver Disease 01/2023 - 01/2023
2	Albuminuria 08/2022 - 01/2021
2	Neoplasms (Cancer) 01/2022 - 01/2018
2	Body Weight Changes 04/2021 - 12/2011
2	Frailty 01/2020 - 01/2014
2	Ischemic Stroke 01/2019 - 10/2016
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2017 - 10/2016
2	Coronary Artery Disease (Coronary Atherosclerosis) 07/2016 - 01/2016
2	Alzheimer Disease (Alzheimer's Disease) 01/2016 - 01/2012
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 03/2024

Drug/Important Bio-Agent (IBA)

43	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 06/2002
39	Insulin (Novolin)FDA Link 03/2024 - 02/2002
21	Liraglutide FDA Link 08/2021 - 04/2010
17	Glucagon-Like Peptide-1 Receptor AgonistsIBA 02/2024 - 01/2008
16	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2022 - 01/2008
12	ertugliflozinIBA 10/2023 - 01/2018
11	semaglutideIBA 01/2023 - 01/2018
11	Insulin Glargine (Lantus)FDA Link 11/2021 - 09/2016
11	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020 - 04/2007
10	omega-Chloroacetophenone (Mace)IBA 01/2023 - 01/2018
10	insulin degludecIBA 11/2021 - 09/2016
10	IncretinsIBA 01/2020 - 04/2007
9	Biomarkers (Surrogate Marker)IBA 10/2023 - 02/2005
9	Metformin (Glucophage)FDA LinkGeneric 04/2021 - 06/2007
8	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 04/2007
7	Glucagon-Like Peptide-1 ReceptorIBA 02/2024 - 07/2017
7	Peptides (Polypeptides)IBA 10/2022 - 01/2009
7	Pioglitazone (Actos)FDA Link 01/2022 - 02/2006
6	Vitamin D FDA LinkGeneric 02/2024 - 11/2017
6	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 07/2023 - 12/2011
6	Proteins (Proteins, Gene)FDA Link 03/2023 - 06/2002
6	Sitagliptin Phosphate (Januvia)FDA Link 04/2021 - 06/2007
5	CreatinineIBA 10/2023 - 01/2020
4	LipidsIBA 01/2024 - 01/2018
4	Blood Glucose (Blood Sugar)IBA 01/2023 - 01/2009
4	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 07/2017
4	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2016
4	Hemoglobins (Hemoglobin)IBA 11/2021 - 01/2018
4	dulaglutideIBA 11/2021 - 01/2018
4	Hormones (Hormone)IBA 01/2020 - 01/2008
4	AdipokinesIBA 07/2016 - 06/2011
4	AdiponectinIBA 10/2012 - 06/2002
3	SodiumIBA 01/2024 - 01/2022
3	C-PeptideIBA 01/2023 - 04/2016
3	Sodium-Glucose Transport ProteinsIBA 01/2023 - 07/2017
3	Volatile Fatty AcidsIBA 01/2023 - 11/2022
3	Exenatide (Byetta)FDA Link 10/2021 - 01/2008
3	SugarsIBA 11/2018 - 03/2004
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 07/2017 - 01/2009
3	CytokinesIBA 10/2012 - 02/2005
3	Amyloid (Amyloid Fibrils)IBA 01/2012 - 07/2008
3	alogliptinIBA 11/2009 - 02/2009
2	rGLP-1 proteinIBA 02/2024 - 04/2014
2	AlbuminsIBA 10/2023 - 01/2020
2	CarbohydratesIBA 01/2023 - 01/2023
2	efpeglenatideIBA 01/2022 - 11/2019
2	Cholecalciferol (Vitamin D3)FDA Link 01/2022 - 11/2017
2	SaccharinIBA 12/2021 - 01/2017
2	glimepiride (Amarel)FDA LinkGeneric 01/2021 - 04/2016
2	LinagliptinIBA 01/2021 - 01/2014
2	Protein Isoforms (Isoforms)IBA 01/2017 - 01/2012
2	Insulin ReceptorIBA 01/2016 - 06/2002
2	ThiazolidinedionesIBA 01/2014 - 02/2009
2	LeptinIBA 10/2012 - 03/2011
2	VildagliptinIBA 01/2009 - 12/2007
2	Interleukin-6 (Interleukin 6)IBA 07/2008 - 02/2005
2	Plasminogen InactivatorsIBA 09/2006 - 07/2006
2	Plasminogen Activator Inhibitor 1IBA 09/2006 - 07/2006

Therapy/Procedure

26	Therapeutics 02/2024 - 04/2007
17	Glycemic Control 10/2022 - 06/2007
4	Injections 10/2021 - 01/2014
3	Bariatric Surgery 01/2021 - 09/2011
2	Secondary Prevention 01/2023 - 02/2006
2	Renal Replacement Therapy (Therapies, Renal Replacement) 10/2021 - 01/2021
2	Polypharmacy 01/2014 - 01/2012